1. Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study*. (1st May 2021) Authors: Reich, K.; Körber, A.; Mrowietz, U.; Sticherling, M.; Sieder, C.; Früh, J.; Bachhuber, T. Journal: British journal of dermatology Issue: Volume 184:Number 5(2021) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study. (18th November 2020) Authors: Reich, K.; Körber, A.; Mrowietz, U.; Sticherling, M.; Sieder, C.; Früh, J.; Bachhuber, T. Journal: British journal of dermatology Issue: Volume 184:Number 5(2021) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study. (1st May 2021) Authors: Reich, K.; Körber, A.; Mrowietz, U.; Sticherling, M.; Sieder, C.; Früh, J.; Bachhuber, T. Journal: British journal of dermatology Issue: Volume 184:Number 5(2021) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study. (31st July 2021) Authors: da Silva, N.; Sommer, R.; Ortmann, C.‐E.; Jagiello, P.; Bachhuber, T.; Augustin, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 11(2021) Page Start: 2241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. (11th September 2018) Authors: Warren, R.B.; Reich, K.; Langley, R.G.; Strober, B.; Gladman, D.; Deodhar, A.; Bachhuber, T.; Bao, W.; Altemeyer, E.; Hussain, S.; Safi, J. Journal: British journal of dermatology Issue: Volume 179:Number 5(2018) Page Start: 1205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. (1st November 2018) Authors: Warren, R.B.; Reich, K.; Langley, R.G.; Strober, B.; Gladman, D.; Deodhar, A.; Bachhuber, T.; Bao, W.; Altemeyer, E.; Hussain, S.; Safi, J. Journal: British journal of dermatology Issue: Volume 179:Number 5(2018) Page Start: 1205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study. (17th October 2019) Authors: Thaçi, D.; Körber, A.; von Kiedrowski, R.; Bachhuber, T.; Melzer, N.; Kasparek, T.; Duetting, E.; Kraehn‐Senftleben, G.; Amon, U.; Augustin, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 2(2020) Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. (1st July 2020) Authors: Augustin, M.; Dauden, E.; Mrowietz, U.; Konstantinou, M.P.; Gerdes, S.; Kingo, K.; Szepietowski, J.C.; Perrot, J.L.; Cuccia, A.; Rissler, M.; Gathmann, S.; Sieder, C.; Orsenigo, R.; Jagiello, P.; Bachhuber, T. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 2(2021) Page Start: 431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. (22nd November 2017) Authors: Körber, A.; Thaçi, D.; von Kiedrowski, R.; Bachhuber, T.; Melzer, N.; Kasparek, T.; Kraehn‐Senftleben, G.; Amon, U.; Augustin, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 3(2018) Page Start: 411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗